These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 21627338

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A, Gillard S, Spino M, Connelly J, Tricta F.
    Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.
    Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, Cuccia L, Spasiano A, Filosa A, Caruso V, Hanif A, Meloni A.
    Clin Drug Investig; 2017 May; 37(5):453-464. PubMed ID: 28185140
    [Abstract] [Full Text] [Related]

  • 6. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Pharmacoeconomics; 2007 Jan; 25(4):329-42. PubMed ID: 17402805
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C.
    Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
    [Abstract] [Full Text] [Related]

  • 15. Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective.
    Li J, Wang P, Li X, Wang Q, Zhang J, Lin Y.
    Mediterr J Hematol Infect Dis; 2020 Oct; 12(1):e2020029. PubMed ID: 32395218
    [Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.
    Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R.
    Curr Med Res Opin; 2008 Jun; 24(6):1609-21. PubMed ID: 18439348
    [Abstract] [Full Text] [Related]

  • 17. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 18. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
    Sruamsiri R, Chaiyakunapruk N, Pakakasama S, Sirireung S, Sripaiboonkij N, Bunworasate U, Hongeng S.
    BMC Health Serv Res; 2013 Feb 05; 13():45. PubMed ID: 23379888
    [Abstract] [Full Text] [Related]

  • 19. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E, Canatan D, Ormeci AR, Vural H, Aylak F.
    J Trace Elem Med Biol; 2013 Apr 05; 27(2):109-11. PubMed ID: 23164519
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun 05; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.